The reasoning is the equivalent of intentionally crashing an ambulance, complaining about having to still meet the needs of patients and then skimping on the cost of repair.
Outcomes just confirm the truly ludicrous and damaging nature of this policy
October 14, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
OncoSil charts a new growth phase as Chairman outlines progress and opportunities
November 19, 2025 - - Latest News -
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech